Ulipristal Acetate for Use in Early Pregnancy Loss

Inclusion Criteria: * Female, age 18 years or older * English- or Spanish-speaking * Ultrasound examination showing a non-viable intrauterine pregnancy between 5- and 12-weeks' gestation or anembryonic gestation * Stated willingness to comply with all study procedures and availability for the duration of the study * Provision of signed and dated informed consent form Exclusion Criteria: * Desire for non-medical management of early pregnancy loss (either expectant management or surgical management) * Hemodynamically unstable * Evidence of incomplete or inevitable abortion (due to high efficacy of misoprostol alone) * Contraindication or allergy to ulipristal acetate or misoprostol (glaucoma, mitral stenosis, sickle cell anemia, chronic glucocorticoid use) * Evidence of a viable intrauterine pregnancy, ectopic pregnancy, or pregnancy with intrauterine device in place * Evidence of pelvic infection * Hemoglobin \<9.5g/dL * Known cardiovascular disease (arrhythmia, cardiac failure, valvular disease, angina) * Known clotting or bleeding disorder, or on anticoagulation therapy * Use of the following medications that may influence metabolization of the study medications: barbiturates, bosentan, carbamazepine, felbamate, griseofulvin, oxcarbazepine, phenytoin, rifampin, St. John's Wort, topiramate * Use of CYP3A4 inhibitors within five elimination half-lives of ulipristal acetate or other strong CYP3A4 inhibitors * Chronic adrenal failure (risk of acute renal insufficiency) * Conc…